BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11410487)

  • 1. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer.
    Papadopoulos I; Sivridis E; Giatromanolaki A; Koukourakis MI
    Clin Cancer Res; 2001 Jun; 7(6):1533-8. PubMed ID: 11410487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
    Arai T; Fujita K; Fujime M; Irimura T
    Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer.
    Papadopoulos I; Rudolph P; Wirth B; Weichert-Jacobsen K
    Urology; 1996 Aug; 48(2):261-8. PubMed ID: 8753738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
    Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
    Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer.
    Ohta S; Wada H; Nakazaki T; Maeda Y; Nobori T; Shiku H; Nakamura S; Nagakawa O; Furuya Y; Fuse H
    Anticancer Res; 2002; 22(5):2991-6. PubMed ID: 12530031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease.
    Di Lorenzo G; De Placido S; Autorino R; De Laurentiis M; Mignogna C; D'Armiento M; Tortora G; De Rosa G; D'Armiento M; De Sio M; Bianco AR; D'Armiento FP
    Prostate Cancer Prostatic Dis; 2005; 8(1):54-9. PubMed ID: 15655565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue factor expression and angiogenesis in human prostate carcinoma.
    Abdulkadir SA; Carvalhal GF; Kaleem Z; Kisiel W; Humphrey PA; Catalona WJ; Milbrandt J
    Hum Pathol; 2000 Apr; 31(4):443-7. PubMed ID: 10821491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Angiogenesis: prognostic marker in prostatic cancer].
    Borre M; Offersen IB; Nerstrøm B; Overgaard J
    Ugeskr Laeger; 1999 Jun; 161(25):3832-6. PubMed ID: 10412301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
    Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
    Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of thymidine phosphorylase correlates with microvessel density in prostate cancer.
    Kataoka A; Yuasa T; Kageyama S; Iwaki H; Higuchi K; Tanaka T; Okada Y; Yoshiki T
    Oncol Rep; 2005 Apr; 13(4):597-600. PubMed ID: 15756429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma.
    Strohmeyer D; Strauss F; Rössing C; Roberts C; Kaufmann O; Bartsch G; Effert P
    Anticancer Res; 2004; 24(3a):1797-804. PubMed ID: 15274358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
    Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
    Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MUC1 expression in human prostate cancer cell lines and primary tumors.
    O'Connor JC; Julian J; Lim SD; Carson DD
    Prostate Cancer Prostatic Dis; 2005; 8(1):36-44. PubMed ID: 15477874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.
    Burke PA; Gregg JP; Bakhtiar B; Beckett LA; Denardo GL; Albrecht H; De Vere White RW; De Nardo SJ
    Int J Oncol; 2006 Jul; 29(1):49-55. PubMed ID: 16773184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between angiogenesis and cyclooxygenase-2 expression in prostate cancer.
    Mukherjee R; Edwards J; Underwood MA; Bartlett JM
    BJU Int; 2005 Jul; 96(1):62-6. PubMed ID: 15963122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of polymorphism in MUC1 tandem repeats in cancer cells is related to breast cancer progression in Japanese women.
    Kawaguchi T; Takazawa H; Imai S; Morimoto J; Watanabe T
    Breast Cancer Res Treat; 2005 Aug; 92(3):223-30. PubMed ID: 16155793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer.
    Wang W; Bergh A; Damber JE
    Clin Cancer Res; 2005 May; 11(9):3250-6. PubMed ID: 15867220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
    Perner S; Hofer MD; Kim R; Shah RB; Li H; Möller P; Hautmann RE; Gschwend JE; Kuefer R; Rubin MA
    Hum Pathol; 2007 May; 38(5):696-701. PubMed ID: 17320151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of different vascular endothelial markers in prostate cancer and BPH tissue: an immunohistochemical and clinical evaluation.
    Trojan L; Thomas D; Friedrich D; Grobholz R; Knoll T; Alken P; Michel MS
    Anticancer Res; 2004; 24(3a):1651-6. PubMed ID: 15274336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.